The value of nasal mupirocin in containing an outbreak of methicillin-resistant Staphylococcus aureus in an orthopaedic unit.
An outbreak of methicillin-resistant Staphylococcus aureus (MRSA) occurred in two adjacent orthopaedic wards following the admission of a known carrier. The outbreak was not contained by ward closure or by standard infection control measures. Eventually several nasal carriers were identified and treated with nasal mupirocin, following which the outbreak ended.
Barrett
S P
SP
Microbiology Department, Southend Hospital, Westcliff-on-Sea, Essex, UK.
D000281:Administration, Intranasal; D000900:Anti-Bacterial Agents / Q000008:administration & dosage / Q000627:therapeutic use*; D003428:Cross Infection / Q000517:prevention & control*; D004203:Disinfection / Q000379:methods; D004739:England; D005227:Fatty Acids / Q000008:administration & dosage / Q000627:therapeutic use; D005260:Female; D006757:Hospital Units; D006801:Humans; D008297:Male; D008712:Methicillin / Q000494:pharmacology*; D016712:Mupirocin; D009985:Orthopedics; D010403:Penicillin Resistance; D013203:Staphylococcal Infections / Q000517:prevention & control*; D013211:Staphylococcus aureus / Q000187:drug effects / Q000302:isolation & purification
D000900:Anti-Bacterial Agents; D005227:Fatty Acids; D016712:Mupirocin; D008712:Methicillin